PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2− Breast Cancer: Clinical and Circulating Tumor DNA Results
Our findings suggest efficacy of PI3K inhibition + tamoxifen beyond second-line treatment and after prior targeted therapies, including CDK4/6 inhibition in metastatic HR+/HER2- breast cancer although the magnitude of benefit did not outweigh the tolerability of this combination. Exploratory biomarker analysis indicates that tumor fraction determined in ctDNA differentiates patients based on prognosis and may help to optimize patient selection for targeted treatment strategies.
Authors
- Marta López‐Yurda (ORCID: https://orcid.org/0000-0003-3678-3222)
- C. Caldas
- Margaret Schot
- Annelot G.J. van Rossum
- R. Bernards
- Sabine Linn
- Karin Beelen
- Richard D. Baird (ORCID: https://orcid.org/0000-0001-7071-6483)
- Catharina M. Korse
- Tatjana T Westphal
- Mafalda Oliveira
- S Manrique Muñoz
- D. Lopez Garcia
- Ingrid A.M. Mandjes
- Mariëtte Schrier
- Cortes Javier
- Karolina Sikorska
- Leonora W. de Boo
- William M. Gallaher
- Rosie A.B. Voorthuis
- Shubha Anand
Institutions
- University College Dublin (IE)
- Hebron University (PS)
- Instituto Cajal (ES)
- Dutch Cancer Society (NL)
- University Medical Center Utrecht (NL)
- Cancer Research UK Cambridge Center (GB)
- Oncode Institute (NL)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2833
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00